Form 4: Immunocore Director Roy Herbst Receives Option Grant

Director Roy Herbst was granted 27,492 stock options in Immunocore Holdings plc as part of an equity compensation award.

Summary

• Director Roy Herbst received a grant of 27,492 share options on May 27, 2026.
• The options have an exercise price of $28.52 per share.
• The options are set to expire on May 26, 2036.
• The award is subject to a vesting schedule tied to the earlier of May 27, 2027, or the day before the next annual general meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying shares relative to the $28.52 exercise price.

Future Outlook

The options vest in one year, signaling the director's continued service and commitment to the company's long-term strategic goals.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to attract and retain high-caliber scientific and clinical expertise.

Comparison to Industry Standards

• The grant size and vesting terms are consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The one-year cliff vesting period is typical for director compensation packages in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on May 27, 2027, or the day prior to the next annual general meeting.

Key Dates

Keywords

Immunocore, IMCR, Director Compensation, Stock Options, Insider Transaction, Biotech